Last updated: 11/04/2018 10:29:10
Parkinson's Disease Patient Study On Absorption, Distribution, Metabolism And Excretion Of Ropinirole
Clinicaltrials.gov ID
EudraCT ID
EU CT Number
Not applicable
Trial status
Completed
Completed
Trial overview
Official title: An open label, repeat dose, dose escalation study conducted in Parkinson's Disease patients to characterize the pharmacokinetics and effect of food on ropinirole prolonged release (PR/CR) 12mg tablets.
Trial description: This study in PD patients is designed to assess the affect food has on the absorption, distribution, metabolism and excretion of ropinirole (by dosing some patients in the fasted state and other patients following a high-fat breakfast), and to assess the difference in absorption, distribution, metabolism and excretion of ropinirole if patients are given three 4mg ropinirole tablets versus one 12mg tablet.
Primary purpose:
Treatment
Trial design:
Crossover Assignment
Masking:
None (Open Label)
Allocation:
Randomized
Primary outcomes:
Ropinirole AUC, the area under the plasma concentration-time curve over 24 hours Ropinirole maximum plasma concentration over 24 hours
Timeframe: 24 hours
Secondary outcomes:
Time to attain the maximum plasma concentration Incidence of adverse events over 37 days As above, but for ropinirole metabolites
Timeframe: over 37 days
Vital signs, ECG and clinical laboratory data over 37 days
Timeframe: over 37 days
Interventions:
Drug: Ropinirole
Enrollment:
28
Observational study model:
Not applicable
Primary completion date:
Not applicable
Time perspective:
Not applicable
Clinical publications:
This study has not been published in the scientific literature.
Medical condition
Parkinson Disease
Product
ropinirole
Collaborators
Not applicable
Study date(s)
April 2007 to August 2007
Type
Interventional
Phase
2
Participation criteria
Sex
Female & Male
Age
30 - 85 years
Accepts healthy volunteers
No
- Male or female patients aged between 30 and 85 years of age
- Body mass index of 18 to 32 kg/m2, body weight of at least 50 kg.
- Patients who have an abnormality on physical examination.
- Patients who have medical conditions which could present a safety concern.
Inclusion and exclusion criteria
Inclusion criteria:
- Male or female patients aged between 30 and 85 years of age
- Body mass index of 18 to 32 kg/m2, body weight of at least 50 kg.
- Diagnosis of idiopathic Parkinson's disease
- Patients must have provided written informed consent prior to performing any study procedures
- QTc interval of < 450ms (or QTc < 480ms in patients with Bundle Branch Block).
Exclusion criteria:
- Patients who have an abnormality on physical examination.
- Patients who have medical conditions which could present a safety concern.
- Patients who have a clinically significant abnormal laboratory value, ECG, or physical examination finding
- Positive result for Hepatitis B surface antigen, Hepatitis C antibody or Human Immunodeficiency Virus (HIV) antibody
- Positive alcohol test result and / or urine test for undeclared drugs
- Recent history of moderate to severe dizziness, syncope, or orthostatic hypotension
- Significant sleep disorder or Epworth Sleep Score (Appendix 5) > 9
- Patients with a lying/sitting diastolic blood pressure =110mmHg or =50mmHg or a systolic blood pressure =180mmHg or =90mmHg
- History of any dopaminergic treatment (other than ropinirole IR and L-dopa) within 2 weeks prior to first dose.
- Withdrawal, introduction, or change in dose of hormone replacement therapy and/or any drug known to substantially inhibit CYP1A2 or induce CYP1A2
- Patients who smoke >20 cigarettes per day and will not maintain a constant smoking habit for the duration of the study.
- Blood donation or significant blood loss less than 90 days before Day 1 of the current study.
- Definite or suspected personal history, or family history, of adverse reactions or hypersensitivity to ropinirole or to drugs with a similar chemical structure.
- Use of any investigational drug (with the exception of ropinirole PR/CR) within 30 days or 5 half lives (whichever is longer) before the start of dosing with study medication.
- Patients who have received over-the-counter (OTC) medicine within 48 h before the first dose of study drug.
- Recent history, or suspicion, of drug dependence or abuse of alcohol
- Significant concern, or likelihood, that the patient will drop out of the study prematurely, will require new or prohibited concomitant medications during the study period, or will not be compliant with study procedures.
- Women who are pregnant or breast-feeding.
- Female patient is currently either of: a) Non-childbearing potential (i.e., physiologically incapable of becoming pregnant, including any female who is post-menopausal or any female who is surgically sterilized (via documented hysterectomy or bilateral tubal ligation). (For purposes of this study, postmenopausal is defined as one year without menses) OR b) child-bearing potential, has a negative urine/serum pregnancy test at the Screening Visit (prior to investigational product administration), and agrees to use acceptable contraception from one month prior to study Day 1 until one month after completion of the study (ie. one month after the follow-up visit). All hormonal birth control must have been administered for at least one monthly cycle prior to the Screening Visit. GSK acceptable contraception methods, when used consistently and in accordance with both the product label and the instructions of a physician, are as follows: -) complete abstinence -) sterilization of patient's male partner prior to female patient's entry into study -) oral contraceptive (either combined or progestogen only) -) any intra-uterine device with a documented failure rate of less than 1% per year -) systemic contraception (eg. norplant system) -) double barrier method if comprised of a spermicide with either a condom or diaphragm
- Patients with prior or current major psychosis
Trial location(s)
Location
GSK Investigational Site
George, Eastern Cape, South Africa, 6529
Status
Study Complete
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Refer to study documents
Recruitment status
Completed
Actual primary completion date
Not applicable
Actual study completion date
2007-29-08
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Participate in clinical trial
Additional information
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Click hereAccess to clinical trial data by researchers
Visit website